An International Observational Study to Assess the Use of Sorafenib After Transarterial Chemoembolization (Tace) in Patients with Hepatocellular Carcinoma (Hcc): Optimis

Jean‐Luc Raoul; Markus Peck‐Radosavljevic; H.C. Lee; Masatoshi Kudo; Keiko Nakajima; Ann‐Lii Cheng

doi:10.1093/annonc/mdu334.128

Back

Shared by

Masatoshi Kudo

An International Observational Study to Assess the Use of Sorafenib After Transarterial Chemoembolization (Tace) in Patients with Hepatocellular Carcinoma (Hcc): Optimis

Article 2014 en

Authors

JR
Jean‐Luc Raoul
MP
Markus Peck‐Radosavljevic
HL
H.C. Lee

Related publications

Article2014

OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Markus Peck‐Radosavljevic, Jean‐Luc Raoul, Han Chu Lee, Masatoshi Kudo, Keiko Nakajima, Ann‐Lii Cheng

Article2015

P1338 : An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): optimis

Markus Peck‐Radosavljevic, Jean‐Luc Raoul, H.C. Lee, Masatoshi Kudo, Keiko Nakajima, Ann‐Lii Cheng

Article2018

Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.

Markus Peck‐Radosavljevic, Masatoshi Kudo, Jean‐Luc Raoul, Han Chu Lee, Thomas Decaens, Jeong Heo, Shi‐Ming Lin, Hong Shan, Yefa Yang, Inga Bayh, Keiko Nakajima, Ann‐Lii Cheng

Article2018

Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.

Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Kohichiroh Yasui, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Yasuaki Arai

Article2018

Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada

Jean‐Luc Raoul, Thomas Decaens, Kelly W. Burak, John Koskinas, Gerda Elisabeth Villadsen, Alexandra Heurgué–Berlot, Inga Bayh, Ann‐Lii Cheng, Masatoshi Kudo, H.C. Lee, Keiko Nakajima, Markus Peck‐Radosavljevic

An International Observational Study to Assess the Use of Sorafenib After Transarterial Chemoembolization (Tace) in Patients with Hepatocellular Carcinoma (Hcc): Optimis

Discussion(0)

Related publications

OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

P1338 : An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): optimis

Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.

Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.

Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada